First, the characterization of CyPD PTMs in the context of AD and/or PD could lead to targeting not directly CyPD itself but rather its modifying enzymes, such as GSK3β [31,127] or SIRT3 [121,122]. Here, SIRT3 is linked to Alzheimer disease.